Epigenomics hit hard as Roche drops collaboration

Shares of Germany's Epigenomics were hammered early today when Roche announced it was ending a collaboration to develop new cancer screening tests after determining Epigenomics' data did not meet its standards. Epigenomics CFO Oliver Schacht told reporters that the company was looking to license its programs in different cancers to different partners, rather than as a group. New deals are likely to take three to six months to complete. In the meantime, its shares plunged more than 50 percent on the news.

- check out Roche's announcement on the decision
- here's the report on Epigenomics from MarketWatch

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.